MOG and myeloid sarcoma: Moreover, the combination of VitD3-tolDC-MOG with IFN-beta treatment resulted in a stronger anti-inflammatory effect and an increased clinical beneficial effect in EAE, suggesting that a combined therapy of antigen-specific cells and immunomodulatory drugs may be a promising new strategy for the treatment of MS patients.